The idea that in COVID-19 patients tocilizumab may suppress the cytokine storm by decreasing the activity of IL-6, is corroborated by the findings of Zarinsefat et al., who speculated on the mechanistic/biologic effects of this drug on immune system cells using an in vitro cytokine storm model of peripheral blood mononuclear cells (PBMC) (30). The gene discussed is IL6; the disease is COVID-19.